Intensive Safety Monitoring of Rituximab (Biosimilar Novex(®) and the Innovator) in Pediatric Patients With Complex Diseases

Although rituximab is widely used off-label for complex pediatric diseases, safety reports are limited. We aimed to report evidence of its use in clinical practice, to describe the incidence of adverse drug reactions (ADR) to rituximab biosimilar Novex(®) and innovator, and to identify risk factors...

Descripción completa

Detalles Bibliográficos
Autores principales: Riva, Natalia, Molina, Manuel, Cornaló, Berta L., Salvador, María V., Savransky, Andrea, Tenembaum, Silvia, Katsicas, María M., Monteverde, Marta, Cáceres Guido, Paulo, Rousseau, Marcela, Staciuk, Raquel, González Correas, Agustín, Zubizarreta, Pedro, Imventarza, Oscar, Lagomarsino, Eduardo, Spitzer, Eduardo, Tinelli, Marcelo, Schaiquevich, Paula
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8827405/
https://www.ncbi.nlm.nih.gov/pubmed/35153748
http://dx.doi.org/10.3389/fphar.2021.785770

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8827405/
https://www.ncbi.nlm.nih.gov/pubmed/35153748
http://dx.doi.org/10.3389/fphar.2021.785770

Ejemplares similares